A systematic review comparing allogeneic hematopoietic stem cell transplant to gene therapy in sickle cell disease

References

• Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89(5):530–535.
   PubMed Web of Science ®Google Scholar
• Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128(10):1436–1438.
   PubMed Web of Science ®Google Scholar
• Bauer DE, Brendel C, Fitzhugh CD. Curative approaches for sickle cell disease: a review of allogeneic and autologous strategies. Blood Cells Mol Dis. 2017;67:155–168.
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Truong TH, Saraf SL, et al. Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and non-myeloablative conditioning in sickle cell disease. Semin Hematol. 2018;55(2):87–93.
   PubMed Web of Science ®Google Scholar
• Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood. 2016;127(7):839–848.
   PubMed Web of Science ®Google Scholar
• Esrick EB, Brendel C, Manis JP, et al. Flipping the switch: initial results of genetic targeting of the fetal to adult globin switch in sickle cell patients [abstract]. Blood. 2018;132(suppl 1):1023.
   Google Scholar
• Hsieh MM, Fitzhugh C, Tisdale J. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197–1207.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• Carreras E, Dufour C, Mohty M, Kroger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer Open; 2019.
   Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617–628.
   PubMed Web of Science ®Google Scholar
• Stenger E, Phelan R, Shaw BE, et al. Excellent overall survival and low incidence of late effects in patients undergoing allogeneic hematopoietic cell transplant for sickle cell disease: a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood. 2019;134(suppl 1):697.
   Google Scholar
• Cochrane handbook for systematic reviews of interventions, Version 5.1.0. 16.1.3.2 Imputing standard deviations for changes from baseline [Internet]. Publication date: 2011 [cited 2022 Apr 20]. 2011 [Available from: https://handbook-5-1.cochrane.org/chapter_16/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm].
   Google Scholar
• Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16(2):263–272.
   PubMed Web of Science ®Google Scholar
• Cochrane handbook for systematic reviews of interventions, Version 5.1.0. 7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means [Internet]. Publication date: 2011 [cited 2022 May 12]. 2011 [Available from: http://handbook-5-1.cochrane.org/chapter_7/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm].
   Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa (CAN): Ottawa Hospital Research Institute; Publication date unknown [cited 2021 Mar 17]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Bernaudin F, Verlhac S, De Latour RP, et al. Association of matched sibling donor hematopoietic stem cell transplantation with transcranial Doppler velocities in children with sickle cell anemia. JAMA. 2019;321(3):266–276.
   PubMed Web of Science ®Google Scholar
• Arnold SD, Jin Z, Sands S, et al. Allogeneic hematopoietic cell transplantation for children with sickle cell disease is beneficial and cost-effective: a single-center analysis. Biol Blood Marrow Transplant. 2015;21(7):1258–1265.
   PubMed Web of Science ®Google Scholar
• Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2013;19(5):820–830.
   PubMed Web of Science ®Google Scholar
• Dedeken L, Le PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol. 2014;165(3):402–408.
   PubMed Web of Science ®Google Scholar
• Bazuaye NG, Enomamien B. Hematopoietic stem cell transplantation (HSCT) for hemoglobinopathy (sickle cell disease) in Nigeria-2013 update by Nigerian group for blood and marrow transplant (NGBMT) [abstract]. Bone Marrow Transplant. 2014;49:S320–S3S1.
   Google Scholar
• Horan JT, Haight A, Dioguardi JL, et al. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial. Biol Blood Marrow Transplant. 2015;21(5):900–905.
   PubMed Web of Science ®Google Scholar
• Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the Phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265–1272.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Isgro A, Sodani P, et al. Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant. 2014;49(11):1376–1381.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Robertson Z, Robinson A, et al. Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center’s experience. Bone Marrow Transplant. 2010;45(5):895–900.
   PubMed Web of Science ®Google Scholar
• Marzollo A, Calore E, Tumino M, et al. Treosulfan-based conditioning regimen in sibling and alternative donor hematopoietic stem cell transplantation for children with sickle cell disease. Mediterr J Hematol Infect Dis. 2017;9(1):e2017014.
   PubMedGoogle Scholar
• McPherson ME, Hutcherson D, Olson E, et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant. 2011;46(1):27–33.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan K, Bhatia M, Geyer MB, et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant. 2013;19(4):676–677.
   PubMed Web of Science ®Google Scholar
• Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood. 2000;95(6):1918–1924.
   PubMed Web of Science ®Google Scholar
• Woodard P, Helton KJ, Khan RB, et al. Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease. Br J Haematol. 2005;129(4):550–552.
   PubMed Web of Science ®Google Scholar
• Zhao J, Beebe K, Magee K, et al. Adolescent male fertility following reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in non-malignant disorders. Pediatr Transplant. 2019;23(6):e13496.
   PubMed Web of Science ®Google Scholar
• Fitzhugh CD, Hsieh MM, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017;1(11):652–661.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Spasojevic I, Morris A, et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Biol Blood Marrow Transplant. 2007;13(12):1422–1426.
   PubMed Web of Science ®Google Scholar
• Oevermann L, Zimmermann C, Voigt S, et al. Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications. Bone Marrow Transplant. 2020;55(1):260–264.
   PubMedGoogle Scholar
• Saraf S, Oh AL, Patel P, et al. Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease. Biol Blood Marrow Transplant. 2018;24(8):1759–1765.
   PubMed Web of Science ®Google Scholar
• van Besien K, Bartholomew A, Stock W, et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000;26(4):445–449.
   PubMed Web of Science ®Google Scholar
• Ozdogu H, Boga C, Yeral M, et al. Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial. Bone Marrow Transplant. 2018;53(7):880–890.
   PubMed Web of Science ®Google Scholar
• Alzahrani M, Damlaj M, Essa M, et al. Outcome of age-adapted approach to HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: Saudi experience [abstract]. Blood. 2018;132(suppl 1):3468.
   Google Scholar
• Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749–2756.
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49(7):913–920.
   PubMed Web of Science ®Google Scholar
• Bhunia N, Abu-Arja R, Bajwa RPS, et al. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease. Pediatr Blood Cancer. 2019;66(10):e27912.
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120(22):4285–4291.
   PubMed Web of Science ®Google Scholar
• De Santis GC, Costa TCM, Santos FLS, et al. Blood transfusion support for sickle cell patients during haematopoietic stem cell transplantation: a single-institution experience. Br J Haematol. 2020;190(5):e295–e2e7.
   PubMed Web of Science ®Google Scholar
• Dhedin N, de la Fuente J, Bernaudin F, et al. Haploidentical bone marrow transplant with post-transplant cytoxan plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international multicenter learning collaborative [abstract]. Blood. 2016;128(22):1233.
   Web of Science ®Google Scholar
• Eckrich MJ, Madden L, Taylor C, et al. Reduced-intensity allogeneic stem cell transplant for sickle cell disease in pediatrics: a single institution experience [abstract]. Biol Blood Marrow Transplant. 2018;24(3):S434–S4S5.
   Google Scholar
• Frangoul H, Evans M, Isbell J, et al. Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy TBI and post transplant cyclophosphamide. Bone Marrow Transplant. 2018;53(5):647–650.
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Monagel DA, Nettel-Aguirre A, et al. Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease. Biol Blood Marrow Transplant. 2019;25(6):1179–1186.
   PubMed Web of Science ®Google Scholar
• Horan JT, Liesveld JL, Fenton P, et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005;35(2):171–177.
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48–56.
   PubMed Web of Science ®Google Scholar
• Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9(8):519–528.
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14(11):1270–1278.
   PubMed Web of Science ®Google Scholar
• Kuentz M, Robin M, Dhedin N, et al. Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease? Blood. 2011;118(16):4491–4492.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90(4):308–312.
   PubMed Web of Science ®Google Scholar
• Mynarek M, Bettoni Da Cunha Riehm C, Brinkmann F, et al. Normalized transcranial Doppler velocities, stroke prevention and improved pulmonary function after stem cell transplantation in children with sickle cell anemia. Klin Padiatr. 2013;225(3):127–132.
   PubMed Web of Science ®Google Scholar
• Pawlowska AB, Cheng JC, Karras NA, et al. HLA haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease. Biol Blood Marrow Transplant. 2018;24(1):185–189.
   PubMed Web of Science ®Google Scholar
• Rangarajan HG, Abu-Arja R, Pai V, et al. Outcomes of unrelated donor stem cell transplantion with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in patients with severe sickle cell disease. Biol Blood Marrow Transplant. 2018;24(2):413–417.
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant. 2016;22(3):441–448.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto J, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561–2567.
   PubMed Web of Science ®Google Scholar
• Shyr D, Leung K, Krance R, et al. A single center experience using myeloablative hematopoietic stem cell transplantation for beta-thalassemia and sickle cell disease [abstract]. Pediatr Blood Cancer. 2012;58(7):1022.
   Web of Science ®Google Scholar
• Soni S, Gross TG, Rangarajan H, et al. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin. Pediatr Blood Cancer. 2014;61(9):1685–1689.
   PubMed Web of Science ®Google Scholar
• Strocchio L, Zecca M, Comoli P, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015;169(5):726–736.
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1–6.
   PubMed Web of Science ®Google Scholar
• Wiebking V, Hutker S, Schmid I, et al. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. Ann Hematol. 2017;96(8):1373–1377.
   PubMed Web of Science ®Google Scholar
• Krishnamurti L, Neuberg D, Sullivan K, et al. Bone marrow transplantation for adolescents and young adults with sickle cell disease: results of a prospective multicenter pilot study. Am J Haematol. 2019;94(4):446–454.
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Volonte B, Rangarajan HG, et al. Abatacept for GVHD prophylaxis after hematopoietic cell transplantation (HCT) for pediatric sickle cell disease (SCD): a sickle cell Transplant Advocacy and Research Alliance (STAR) trial [abstract]. Biol Blood Marrow Transplant. 2020;26(S20).
   Google Scholar
• Foell J, Kleinschmidt K, Jakob M, et al. Alternative donor: alphas/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease. Hematol Oncol and Stem Cell Ther. 2020;13(2):98–105.
   PubMedGoogle Scholar
• Magrin E, Semeraro M, Magnani A, et al. Results from the completed HGB-205 trial of lentiglobin for beta-thalassemia and lentiglobin for sickle cell disease gene therapy [abstract]. Blood. 2019;134:3358.
   Web of Science ®Google Scholar
• Thompson AA, Walters MC, Mapara MY, et al. Resolution of serious vaso-occlusive pain crises and reduction in patient-reported pain intensity: results from the ongoing phase 1/2 HGB-206 Group C Study of LentiGlobin for sickle cell disease (bb1111) gene therapy [abstract]. Blood. 2020;136:16–17.
   Web of Science ®Google Scholar
• Esrick EB, Achebe M, Armant M, et al. Validation of BCL11A as therapeutic target in sickle cell disease: results from the adult cohort of a pilot/feasibility gene therapy trial inducing sustained expression of fetal hemoglobin using post-transcriptional gene silencing [abstract]. Blood. 2019;134(Suppl 2):LBA5.
   Google Scholar
• Adamkiewicz TV, Mehta PS, Boyer MW, et al. Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. Bone Marrow Transplant. 2004;34(5):405–411.
   PubMed Web of Science ®Google Scholar
• Abraham A, Stenger E, Travers CD, et al. Similar event-free survival but higher incidence of mixed T cell chimerism after hematopoietic cell transplantation for sickle cell disease using rabbit versus horse ATG: A study from the Sickle Transplant Alliance for Research (STAR) [abstract]. Blood. 2017;130(Suppl 1):3535.
   Google Scholar
• Covi S, Ravindranath Y, Farooqi A, et al. Changes in bi-ventricular function after hematopoietic stem cell transplant as assessed by speckle tracking echocardiography. Pediatr Cardiol. 2018;39(2):365–374.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Gaziev J, Isgro A, et al. Allogeneic cellular gene therapy in hemoglobinopathies-evaluation of hematopoietic SCT in sickle cell anemia. Bone Marrow Transplant. 2012;47(2):227–230.
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Sureda A. Chapter 41: graft failure. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies [internet]. 7th Ed. Carreras E, Dufour C, Mohty M, editors. Cham (CH): Springer; 2019.
   Google Scholar
• Al-Musalhi M, Al-Zadjali S, Al-Huneini M, et al. Stable mixed chimerism after hematopoietic stem cell transplantation in patients with sickle cell disease [abstract]. Bone Marrow Transplant. 2017;52(Suppl 1):96.
   Google Scholar
• Biernacki MA, Okam M, Shenoy S, et al. Long-term follow-up of adults with severe sickle cell disease after hematopoietic stem cell transplantation using reduced intensity conditioning [abstract]. Blood. 2010;116(21):261.
   Google Scholar
• Hsieh MM, Bonner M, Pierciey FJ, et al. Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Adv. 2020;4(9):2058–2063.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study evaluating the safety and efficacy of bb1111 in severe sickle cell disease [NCT02140554] [updated December 29, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02140554].
   Google Scholar
• ClinicalTrials.gov. A study evaluating the safety and efficacy of LentiGlobin BB305 Drug Product in β-thalassemia major (also referred to as transfusion-dependent β-thalassemia [TDT]) and sickle cell disease [NCT02151526] [updated April 26, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02151526].
   Google Scholar
• Bhatia M, Kolva E, Cimini L, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21(4):666–672.
   PubMed Web of Science ®Google Scholar
• Kanter J, Tisdale J, Mapara M, et al. Improvements in health-related quality of life for patients treated with LentiGlobin for sickle cell disease (bb1111) gene therapy [abstract]. Blood. 2020;136:365.
   Web of Science ®Google Scholar
• Sachdev V, Hsieh M, Jeffries N, et al. Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease. Blood Adv. 2019;3(19):2816–2824.
   PubMed Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855.
   PubMed Web of Science ®Google Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386:138–147.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Center for Biologics Evaluation and Research. Long term follow-up after administration of human gene therapy products: guidance for industry. 2020 [updated January 2020. Available from: https://www.fda.gov/media/113768/download].
   Google Scholar
• Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv. 2021;5(2):570–583.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Longterm follow-up of subjects with hemoglobinopathies treated with ex vivo gene therapy [NCT02633943] [updated April 26, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02633943].
   Google Scholar
• Eapen M, Brazauskas R, Walters MC, et al. Impact of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with Sickle Cell Disease: a retrospective, cohort study. Lancet Haematol. 2019;6(11):e585–ee96.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548–1556.
   PubMed Web of Science ®Google Scholar
• Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev. 2020;7(7):CD007001.
   PubMedGoogle Scholar
• Dennison D, Al Farsi K, Al Huneini M, et al. Hematopoietic stem cell transplantation for sickle cell anemia with busulfan-based reduced intensity conditioning: cure and fertility [abstract]. Biol Blood Marrow Transplant. 2013;19(2):S285–S2S6.
   Google Scholar
• Williams KM, Dietzen D, Hassoun AA, et al. Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease. Pediatr Blood Cancer. 2014;61(12):2307–2309.
   PubMed Web of Science ®Google Scholar
• Bhunia N, Abu-Arja R, Bajwa RPS, et al. Eculizumab to treat posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients receiving allogeneic hematopoietic cell transplant for sickle cell disease [abstract]. Biol Blood Marrow Transplant. 2019;25(S140).
   PubMedGoogle Scholar
• Chaudhury S, Laskowski J, Rangarajan HG, et al. Abatacept for GVHD prophylaxis after hematopoietic stem cell transplantation (HCT) for pediatric sickle cell disease (SCD): A sickle transplant alliance for research (STAR) trial [abstract]. Biol Blood Marrow Transplant. 2018;24(3):S91.
   PubMedGoogle Scholar
• Covi S, Ravindranath Y, Farooqi A, et al. Effect of hematopoietic stem cell transplantation on bi-ventricular function as assessed by speckle tracking echocardiography [abstract]. J Am Soc Echocardiogr. 2016;29(6):B92.
   Google Scholar
• Dedeken L, Le PQ, Azzi N, et al. Hematopoietic stem cell transplantation for sickle cell disease in childhood: A single center experience with 45 patients [abstract]. Blood. 2011;118(21):3103.
   Google Scholar
• Brachet C, Azzi N, Demulder A, et al. Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation’s outcome. Bone Marrow Transplant. 2004;33(8):799–803.
   PubMed Web of Science ®Google Scholar
• Brachet C, Heinrichs C, Tenoutasse S, et al. Children with sickle cell disease: growth and gonadal function after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2007;29(7):445–450.
   PubMed Web of Science ®Google Scholar
• Foell J, Schulte J, Troeger A, et al. Stem cell transplantation in advanced stage sickle cell disease with haploidentical T-cell depleted PBSC yields comparable outcomes to matched sibling donor bone marrow: results of a pilot study [abstract]. Blood. 2018;132:3455.
   Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309–2317.
   PubMed Web of Science ®Google Scholar
• Isgro A, Diomedi M, Sodani P, et al. Hematopoietic stem cell transplantation for the black African variants of sickle cell anemia: TCD and brain MRI before transplant [abstract]. Cerebrovasc Dis. 2014;37:42–43.
   Web of Science ®Google Scholar
• Isgro A, Gaziev J, Sodani P, et al. Hematopoietic stem cell transplantation in Nigerian children with sickle cell anemia [abstract]. Blood. 2015;126(23):4598.
   Google Scholar
• Isgro A, Gaziev J, Sodani P, et al. Hematopoietic stem cell transplantation in Nigerian children with sickle cell anemia [abstract]. Bone Marrow Transplant. 2016;51:S254–S2S5.
   Google Scholar
• Isgro A, Paciaroni K, Gaziev J, et al. Hematopoietic stem cell transplantation in sickle cell anemia children patients [abstract]. Bone Marrow Transplant. 2015;50:S46.
   Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Update on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy [abstract]. Haematologica. 2017;102:248.
   Web of Science ®Google Scholar
• Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Update from the Hgb-205 phase 1/2 clinical study of lentiglobin gene therapy: sustained clinical benefit in severe hemoglobinopathies [abstract]. Blood. 2016;128(22):2311.
   Web of Science ®Google Scholar
• Cavazzana M, Hacein-Bey-Abina S, Payen E, et al. Longer term follow-up on the first patients with severe hemoglobinopathies treated with lentiglobin gene therapy [abstract]. Blood. 2017;130(Suppl 1):4609.
   Google Scholar
• Cavazzana M, Ribeil JA, Payen E, et al. Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector [abstract]. Blood. 2015;126(23):202.
   Google Scholar
• Cavazzana M, Ribeil JA, Payen E, et al. Outcomes of gene therapy for b-thalassemia major and severe sickle disease via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta globin vector [abstract]. Haematologica. 2015;100:171.
   Google Scholar
• Cavazzana M, Ribeil JA, Payen E, et al. Clinical outcomes of gene therapy with BB305 lentiviral vector for sickle cell disease and beta-thalassemia [abstract]. Mol Ther. 2016;24:S111–S1S2.
   Web of Science ®Google Scholar
• Hebert N, Magrin E, Miccio A, et al. Analysis of RBC properties in patients with SCD treated with lentiglobin gene therapy [abstract]. Blood. 2018;132(Suppl 1):2195.
   Google Scholar
• Soni S, Tisdale JF, Hsieh M, et al. Outcomes of gene therapy for severe sickle cell disease (SCD) via transplantation of autologous hematopoietic stem cells transduced Ex vivo with a lentiviral beta AT87Q-globin vector. Biol Blood Marrow Transplant. 2016;22(3):S63.
   Google Scholar
• King AA, McKinstry RC, Wu J, et al. Functional and radiologic assessment of the brain after reduced-intensity unrelated donor transplantation for severe sickle cell disease: blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant. 2019;25(5):e174–e1e8.
   PubMed Web of Science ®Google Scholar
• Thompson AA, Tisdale JF, Kanter J, et al. Lentiglobin gene therapy in patients with sickle cell disease: updated interim results from HGB-206 [abstract]. Br J Haematol. 2019;185:22–23.
   Web of Science ®Google Scholar
• Mapara MY, Tisdale JF, Kanter J, et al. Lentiglobin gene therapy in patients with sickle cell disease: updated interim results from Hgb-206 [abstract]. Biol Blood Marrow Transplant. 2019;25:S64–SS5.
   Web of Science ®Google Scholar
• Kanter J, Thompson A, Mapara M, et al. Recent progress in gene therapy for severe sickle cell disease: updated interim results from a phase 1 clinical study of lentiglobin gene therapy. HemaSphere. 2018;2(Suppl 2):368.
   Google Scholar
• Kanter J, Walters MC, Hsieh M, et al. Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease [abstract]. Blood. 2017;130(Suppl 1):527.
   PubMedGoogle Scholar
• Kanter J, Walters MC, Hsieh MM, et al. Interim results from a phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease [abstract]. Blood. 2016;128(22):1176.
   Web of Science ®Google Scholar
• Kanter J, Walters MC, Hsieh M, et al. Initial results from study HGB-206: A phase 1 study evaluating gene therapy by transplantation of autologous CD34+ stem cells transduced ex vivo with the lentiglobin BB305 lentiviral vector in subjects with severe sickle cell disease. Blood. 2015;126(23):3233.
   Web of Science ®Google Scholar
• Tisdale JF, Kanter J, Hsieh M, et al. Single-agent plerixafor mobilization to collect autologous stem cells for use in gene therapy for severe sickle cell disease [abstract]. Biol Blood Marrow Transplant. 2018;24(3):S174.
   Web of Science ®Google Scholar
• Tisdale JF, Pierciey FJ, Kamble R, et al. Successful plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease [abstract]. Blood. 2017;130:990.
   Web of Science ®Google Scholar
• Bonner M, Kanter J, MacAri E, et al. The relationships between target gene transduction, engraftment of HSCs and RBC physiology in sickle cell disease gene therapy [abstract]. Blood. 2019;134:206.
   Web of Science ®Google Scholar
• Kanter J, Tisdale JF, Mapara MY, et al. Resolution of sickle cell disease manifestations in patients treated with lentiglobin gene therapy: updated results from the phase 1/2 hgb-206 group c study [abstract]. Blood. 2019;134:990.
   Web of Science ®Google Scholar
• Walters MC, Kanter J, Kwiatkowski JL, et al. Lentiglobin for sickle cell disease (SCD) gene therapy (GT): updated results in group C patients from the phase 1/2 Hgb-206 study [abstract]. Biol Blood Marrow Transplant. 2020;26:S1–S2.
   PubMed Web of Science ®Google Scholar
• Walters MC, Tisdale JF, Kwiatkowski JL, et al. Exploring the drivers of potential clinical benefit in initial patients treated in the Hgb-206 study of lentiglobin for sickle cell disease (SCD) gene therapy [abstract]. Blood. 2019;134:2061.
   Web of Science ®Google Scholar